Tirzepatide: A Dual GIP/GLP-1 Receptor Agonist in Metabolic and Obesity Research

Overview

Tirzepatide (CAS 2023788-19-2) is a 39-amino acid synthetic peptide that functions as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Unlike earlier GLP-1 receptor agonists, tirzepatide's dual mechanism provides complementary and potentially synergistic effects on insulin secretion, appetite regulation, and energy homeostasis. Its molecular formula is C225H348N48O68 with a molecular weight of approximately 4,813.5 Da.

The peptide was developed as a once-weekly subcutaneous injection and has been the subject of extensive clinical investigation under the SURPASS and SURMOUNT trial programs. Research findings have consistently demonstrated superior reductions in HbA1c and body weight compared to existing GLP-1 monotherapy agents, making tirzepatide one of the most studied compounds in contemporary metabolic research.

Mechanism of Action

Tirzepatide exerts its effects through simultaneous activation of two incretin hormone receptors. The GIP receptor, expressed primarily in pancreatic beta cells, adipose tissue, and the central nervous system, plays a role in potentiating glucose-stimulated insulin secretion and modulating lipid metabolism. The GLP-1 receptor, expressed in the pancreas, hypothalamus, and gastrointestinal tract, mediates insulin secretion, glucagon suppression, gastric emptying delay, and satiety signaling.

The co-agonism of both receptors appears to produce additive or synergistic effects not achievable with GLP-1 receptor agonism alone. Research suggests that GIP receptor activation may enhance the tolerability of GLP-1 receptor stimulation while contributing independently to fat mass reduction through direct effects on adipocytes. The peptide's C18 fatty diacid moiety enables albumin binding, extending its plasma half-life to approximately five days and supporting once-weekly dosing in research protocols.

Key Research Findings

The SURPASS clinical trial program evaluated tirzepatide across multiple Phase 3 studies in subjects with type 2 diabetes. SURPASS-2 demonstrated that tirzepatide at 15 mg produced mean HbA1c reductions of 2.46% compared to 1.86% with semaglutide 1 mg, alongside greater reductions in body weight (−11.2 kg vs −5.7 kg). These findings were published in the New England Journal of Medicine in 2021.

The SURMOUNT-1 trial, published in 2022, investigated tirzepatide in subjects with obesity (BMI ≥30) without type 2 diabetes. At the 15 mg dose, participants achieved a mean weight reduction of 22.5% from baseline over 72 weeks — a magnitude approaching that observed with bariatric surgical interventions. Approximately 57% of participants receiving 15 mg achieved ≥20% weight loss.

Beyond glycemic and weight outcomes, research has explored tirzepatide's effects on cardiovascular risk factors, hepatic steatosis, sleep apnea, and kidney function. The SURPASS-CVOT trial is ongoing and will provide definitive cardiovascular outcome data.

Chemical Properties

| Property | Value | |---|---| | Molecular Formula | C₂₂₅H₃₄₈N₄₈O₆₈ | | Molecular Weight | ~4,813.5 Da | | CAS Number | 2023788-19-2 | | Form | Lyophilized powder | | Purity (research grade) | ≥99% HPLC | | Storage | −20°C, protect from light |

Research Considerations

Tirzepatide for research use is supplied as a lyophilized powder requiring reconstitution with bacteriostatic water prior to use. Reconstituted solutions should be stored at 2–8°C and used within 28 days. Research protocols should account for the peptide's extended half-life when designing dosing intervals. As with all GLP-1/GIP receptor agonists, gastrointestinal effects have been observed in clinical research and should be considered in study design.

Research Use Only. This article is for scientific and educational reference. All products are sold for research purposes only and are not intended for human or animal consumption. Not for use in food, drug, medical device, or cosmetic manufacturing.